Alterity Therapeutics Ltd

Discover how Alterity Therapeutics CEO’s option holdings signal long‑term confidence, the impact on investor strategy, and what it means for the company’s phase‑III trial and future valuation.

Alterity Therapeutics CFO’s option buy signals optimism after a plunge to $0.01, hinting at future milestones while the company remains a high‑risk, early‑stage biotech.